Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumicitabine TQT and Dose Escalation Study in Healthy Subjects
NCT02833831Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lumicitabine in respiratory syncytial virus infection (RSV) (9 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in Corrected QT intervals (QTc) at Day 2. Started Jun 2016; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02833831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833831.